# Anlotinib and Benmelstobart in DTC

> **NCT07193186** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 23 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Anlotinib and Benmelstobart

## Key facts

- **NCT ID:** NCT07193186
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07193186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07193186, "Anlotinib and Benmelstobart in DTC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07193186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*